DOCSLIB.ORG

Strategic Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Strategic Report Annual Report 2020 We are a science-led global healthcare company 2020 performance summary £34.1bn AER +1% £9.7bn AER +11% Group turnover CER +3% New and specialty medicines CER +12% £7.8bn AER +12% £8.9bn AER - 1% Total operating profit CER +15% Adjusted operating profit CER +2% 115.5p AER +23% 115.9p AER - 6% Total earnings per share CER +26% Adjusted earnings per share CER - 4% 9 80p 1st 2nd major pipeline Dividend in the Access to in the pharmaceutical approvals Medicine Index industry for Dow Jones Sustainability Index Contents Strategic report Our business model 01 Board roles and responsibilities 86 Financial statements of Chairman’s statement 03 Board activity and principal decisions 87 GlaxoSmithKline plc prepared CEO’s statement 04 Our purpose, values and culture 90 under UK GAAP 238 Financial performance 06 The Board’s approach to engagement 91 Our long-term priorities 09 Board performance 94 Investor information Our culture 10 Board Committee information 96 Quarterly trend 244 Key performance indicators 11 Our Board Committee reports 97 Five-year record 249 Industry trends 12 Section 172 statement 108 Product development pipeline 255 Stakeholder engagement 16 Directors’ report 109 Products, competition and Innovation 18 intellectual property 258 Remuneration report Performance 28 Principal risks and uncertainties 261 Trust 33 Chairman’s annual statement 112 Share capital and share price 276 Risk management 43 Annual report on remuneration 114 Dividends 278 Group financial review 50 2020 Remuneration policy summary 133 Financial calendar 2021 279 Annual General Meeting 2021 279 Corporate Governance Financial statements Tax information for shareholders 280 Chairman’s Governance statement 78 Directors’ statement of Shareholder services and contacts 282 The Board 80 responsibilities 140 US law and regulation 284 Corporate Executive Team 83 Independent Auditor’s report 142 Group companies 287 Board architecture 85 Financial statements 154 Glossary of terms 299 Notes to the financial statements 158 Cautionary statement See the inside back cover of this document for the cautionary statement regarding forward-looking statements. Non-IFRS measures We use a number of adjusted, non-IFRS, measures to report the performance of our business. Total reported results represent the Group's overall performance under IFRS. Adjusted results, pro-forma growth rates and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Adjusted results and other non-IFRS measures are defined on pages 51 to 53 and reconciliations to the nearest IFRS measures are on pages 64 and 68. Strategic report Governance and remuneration Financial statements Investor information Our business model Every day, we help improve the health of millions of people around the world by discovering, developing and manufacturing innovative medicines, vaccines and consumer healthcare products. Our operations span the value chain from identifying, Performance is delivered by investing effectively in our researching, developing and testing ground breaking business and our people and executing competitively. discoveries, to regulatory approval, manufacturing and Our ability to launch new products successfully and commercialisation. We remained resilient through a grow sales from our existing portfolio is key to our challenging year for the world by being agile and maintaining commercial success. focus on our purpose and strategic long-term priorities. Trust is also critical to our success. We are a responsible Central to our success are our people: experts in company and commit to use our science and technology science, technology, regulation, intellectual property and to address health needs, make our products affordable commercialisation. We also collaborate with world-leading and available, and be a modern employer. Our 13 public experts and form strategic partnerships to complement commitments support our Trust priority and cover a broad our existing capabilities. range of environmental, social and governance (ESG) aspects. Our purpose and strategy The commitments are designed to help us respond to ESG Our purpose is to improve the quality of human life by challenges and opportunities within our industry and society helping people do more, feel better and live longer. It guides more broadly and contribute to many of the UN Sustainable all of our actions and is key to the delivery of our strategy Development Goals particularly Goal 3: ensure healthy lives – to bring differentiated, high-quality and needed healthcare and promote wellbeing. products to as many people as possible, preventing and The value we create treating disease and keeping people well with our scientific By delivering on our purpose, the greatest contribution we and technical know-how and talented people. make is to improve the health of people around the world. Our long-term priorities In 2020 that included delivering 2.2 billion packs of medicines, Our priorities of Innovation, Performance and Trust are over 580 million vaccine doses and 3.8 billion consumer underpinned by our ambition to build a more purpose and healthcare products. performance driven culture, aligned to our values – patient For our shareholders, as part of our capital allocation focus, transparency, respect and integrity – and expectations framework, we invest in our business to provide shareholder – courage, accountability, development and teamwork. returns. In 2020 we paid a dividend of 80p per share and Innovation is critical to how we improve health and create delivered £5.4 billion of free cash flow. financial value. In 2020 Total R&D expenditure was £5.1 billion, We make a positive contribution to the communities in which was 15.0% of turnover, and an increase of 12% (AER which we operate. We employ over 94,000 people across and CER) from the previous year. On an Adjusted basis, R&D 96 countries and work directly with 36,000 suppliers. expenditure was £4.6 billion (13.5% of turnover), 6% higher at In 2020 we paid £1.7 billion in corporation tax. We also AER, 7% higher at CER, than in 2019. On a pro-forma basis, pay a significant amount of other business and employment Adjusted R&D expenditure grew 6% CER compared with 2019. related taxes. We aim to be a modern employer and offer a In Pharmaceuticals and Vaccines, we focus on science broad range of employee benefits, including preventative related to the immune system, human genetics and advanced healthcare services, so that we are able to attract and technology. In Consumer Healthcare we leverage our scientific retain the best people. expertise and deep consumer insights to create healthcare products that meet consumer demands. As a research-based healthcare company we rely on intellectual property protection to help ensure a reasonable return on our investments so we can continue to research and develop new and innovative medicines. GSK Annual Report 2020 01 Our business model continued Preparing for the future Creating two new companies During the year we achieved an important milestone with the In early 2020, consistent with our strategic priorities and launch of our One Development organisation in R&D. This is previous announcements, we started a two-year programme already enabling us to be even more effective in how we allocate to prepare GSK for separation into two new leading companies: our budget, share technical and scientific expertise and deliver New GSK, a new biopharma company, focused on specialty our pipeline, regardless of modality. medicines and vaccines with an R&D approach focused on Under the programme, we are seeking to improve our the science related to the immune system, the use of human capabilities and create efficiencies in our global support genetics and new technologies; and a new leader in consumer functions; continuing to simplify and focus our manufacturing healthcare with category-leading power brands and innovation network, ensuring our supply chain is ready to launch our new based on science and consumer insights. specialty medicines; and rationalising our portfolio through We are on track for separation into new standalone Biopharma divestments. and Consumer Healthcare companies in 2022. For the new Consumer Healthcare company, this programme The programme is using the unique catalyst of separation is supporting the building of key technology infrastructure and to reset the capabilities and cost base for both companies, the expertise necessary to operate as a standalone company. and help support delivery of the significant value creation We believe that increased investment in our pipeline and new opportunities we see in both New GSK and new Consumer products, together with effective implementation of our two-year Healthcare. programme, will set each new company up with strong For New GSK, we see a clear opportunity to drive a common foundations for future performance. approach to R&D as the science related to the immune system The financial benefits, costs and reporting associated with the converges across both pharmaceuticals and vaccines. programme are set out on pages 65 and 66. Capital allocation Capital allocation framework Key priorities for capital Invest in the business – R&D pipeline (including business development) – Vaccines capacity Innovation – New products Improved Shareholder returns – Dividends Performance cash – Target 1.25x to 1.5x cover before generation returning dividend to growth Trust Other M&A – Strict discipline on returns
Load more

Recommended publications
  • Randomised Trial to Compare the Immunogenicity and Safety of a CRM Or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenag
    Title Page Randomised trial to compare the immunogenicity and safety of a CRM or TT 1 2 conjugated quadrivalent meningococcal vaccine in teenagers who received a 3 4 5 CRM or TT conjugated serogroup C vaccine at preschool age 6 7 8 9 1,2 1,3 1 10 David A. Ishola , FFPH; Nick Andrews , PhD; Pauline Waight , BSc; Chee-Fu 11 12 Yung1,6, FFPH; Jo Southern1, PhD; Xilian Bai4, PhD; Helen Findlow4, PhD; Mary 13 14 5 5 5 4 15 Matheson , PhD; Anna England , MSc; Bassam Hallis , PhD; Jamie Findlow , PhD; 16 4 1 17 Ray Borrow , PhD; Elizabeth Miller , FRCPath. 18 19 1. Immunisation Department, Public Health England (PHE), London, UK 20 21 22 2. Department of Infection and Population Health, University College London, 23 24 London, UK 25 26 27 3. Statistics, Modelling, and Economics Department, PHE London, UK 28 29 4. Vaccine Evaluation Unit, PHE, Manchester Medical Microbiology Partnership, 30 31 32 Manchester Royal Infirmary, Manchester, UK 33 34 5. Microbiology Services, PHE, Porton Down, Salisbury, UK 35 36 6. Department of Clinical Epidemiology, Communicable Disease Centre, Tan Tock 37 38 39 Seng Hospital, Singapore. 40 41 Correspondence: David Ishola, University College London, Department of Infection 42 43 44 and Population Health, 222 Euston Road, London NW1 2DA, UK. Tel: +44 45 46 (0)7946412701. Fax: +44 (0)20 83277404. E-mail: [email protected] 47 48 49 Address for reprints: Not applicable (reprints not available). 50 51 Key words: Meningococcal, vaccine, teenagers, antibody, randomised trial 52 53 54 Abbreviated title: Teenage MenACWY booster vaccination: Randomised trial 55 56 Running head title: Teenage MenACWY booster vaccination 57 58 59 60 61 62 1 63 64 65 CONFLICTS OF INTEREST AND SOURCE OF FUNDING: 1 2 Funding and support: This report is independent research commissioned and 3 4 5 funded by the UK Department of Health Policy Research Programme (National 6 7 Vaccine Evaluation Consortium, 039/0031).
    [Show full text]
  • The NHS's Role in the Public's Health
    The NHS’s role in the public’s health A report from the NHS Future Forum Workstream members Vicky Bailey ‐ Chair, NHS’s role in the public’s health group Chief Operating Officer, Principia Rushcliffe Clinical Commissioning Group Ash Soni ‐ Chair, NHS’s role in the public’s health group Community Pharmacist; Clinical Network Lead, NHS Lambeth Dr Charles Alessi Senior GP Partner, The Churchill Practice Dr Frank Atherton President, Association of Directors of Public Health; Director of Public Health, North Lancashire Cluster Ratna Dutt Chief Executive, Race Equality Foundation Paul Farmer Chief Executive, Mind Moira Gibb Chief Executive, London Borough of Camden; Chair, Social Work Task Force Chris Long Chief Executive, Humber Cluster Claire Marshall Head of Professions, Heatherwood and Wexham Park Hospitals NHS Foundation Trust Dr Tim Riley Chief Executive, Wellstate Group Ltd Tom Riordan Chief Executive, Leeds City Council Dr Robina Shah Chair, Stockport NHS Foundation Trust Professor Jimmy Steele Head of School and Professor of Oral Health Services Research, School of Dental Sciences, Newcastle University Gill Walton Director of Midwifery, Portsmouth Hospitals NHS Trust Contents Contents.........................................................................................................................2 Foreword........................................................................................................................3 Terms used in this report...............................................................................5
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Research Strategy 2015-2018 Public Health Wales Research Strategy 2015–2018
    Research Strategy 2015-2018 Public Health Wales Research Strategy 2015–2018 01 ForewordText Public health covers a broad range of activities. These include primary prevention, surveillance and early detection of disease, control and management of communicable diseases and environmental threats, improving healthcare quality, informing policy and implementing interventions and programmes to improve population health and wellbeing. The public health challenges in Wales are similar Public Health Wales’ Integrated Medium Term Plan Integration between to many post-industrial societies, with an ageing for 2015-2018 clearly identifies a suite of priority population and high prevalence of chronic conditions areas for action. Integration between public health public health research, such as diabetes and cardiovascular disease. Health research, policy and practice will be essential for us policy and practice will be inequalities persist in many areas, and the gap in to drive forward improvements in population health healthy life expectancy between the most and least and wellbeing. We therefore welcome this research essential for us to drive deprived areas is 18 years. For example, 25% of strategy, which aims to develop research capacity forward improvements children aged four to five are overweight or obese, and capability within Public Health Wales. Successful while 22% of adults are obese, with higher prevalence implementation of this strategy over the next three in population health and in more deprived areas. Similar profiles exist for years
    [Show full text]
  • Annual Report and Accounts 2018/19
    Annual report and accounts 2018/19 HC 2479 Care Quality Commission Annual report and accounts 2018/19 Presented to Parliament pursuant to paragraph 10(4) of Schedule 1 of the Health and Social Care Act 2008. Ordered by the House of Commons to be printed on 24 July 2019. HC 2479 © Care Quality Commission copyright 2019 The text of this document (this excludes, where present, the Royal Arms and all departmental or agency logos) may be reproduced free of charge in any format or medium provided that it is reproduced accurately and not in a misleading context. The material must be acknowledged as Care Quality Commission copyright and the document title specified. Where third party material has been identified, permission from the respective copyright holder must be sought. Any enquiries related to this publication should be sent to us at [email protected]. This publication is available at www.gov.uk/official-documents. ISBN 978-1-5286-1521-1 ID CCS0619531556 07/19 Printed on paper containing 75% recycled fibre content minimum. Printed in the UK by APS Group on behalf of the Controller of Her Majesty’s Stationery Office. Contents Who we are and what we do 2 Performance report 4 Foreword 5 Performance summary 7 Performance analysis 11 Accountability report 51 Corporate governance report 52 Remuneration and people report 68 Parliamentary accountability and audit report 82 Certificate and report of the Comptroller and Auditor General 84 to the Houses of Parliament Financial statements 87 Statement of Comprehensive Net Expenditure 88 Statement of Financial Position 89 Statement of Cash Flows 90 Statement of Changes in Taxpayers’ Equity 91 Notes to the financial statements 92 Who we are and what we do Who we are and what we do Who we are: The Care Quality Commission (CQC) is the independent regulator of health and adult social care in England.
    [Show full text]
  • The State of Health Care and Adult Social Care in England 2015/16 @Carequalitycomm
    Care Quality Commission Care The state of health How to contact us in England and adult social care of health care The state care and adult social Call us on 03000 616161 care in England Email us at [email protected] Look at our website www.cqc.org.uk 2015/16 Write to us at Care Quality Commission Citygate Gallowgate Newcastle upon Tyne NE1 4PA 2015/16 Follow us on Twitter @CareQualityComm Read the summary and download this report in other formats at www.cqc.org.uk/stateofcare Scan this code on your phone to visit the site now. Please contact us if you would like this report in another language or format. CQC-347-410-102016 Care Quality Commission The state of health care and adult social care in England 2015/16 Presented to Parliament pursuant to section 83(4)(a) of the Health and Social Care Act 2008. Ordered by the House of Commons to be printed on 12 October 2016. HC 706 © Care Quality Commission 2016 The text of this document (this excludes, where present, the Royal Arms and all departmental and agency logos) may be reproduced free of charge in any format or medium providing that it is reproduced accurately and not in a misleading context. The material must be acknowledged as Care Quality Commission copyright and the document title specified. Where third party material has been identified, permission from the respective copyright holder must be sought. Any enquiries regarding this publication should be sent to us at [email protected] This publication is available at https://www.gov.uk/government/publications Print: ISBN 9781474137553 Web: ISBN 9781474137560 Printed in the UK by the Williams Lea Group on behalf of the Controller of Her Majesty’s Stationery Office.
    [Show full text]
  • A Guide to Community-Centred Approaches for Health and Wellbeing
    A guide to community-centred approaches for health and wellbeing Full report Community-centred approaches for health and wellbeing About Public Health England Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland Prepared by: Professor Jane South Supported by: Jude Stansfield, Pritti Mehta and advisory group: Anne Brice, Ann Marie Connolly, Catherine Davies, Gregor Henderson, Paul Johnstone (PHE), Olivia Butterworth, Luke O’Shea, Giles Wilmore (NHS England). Also Dave Buck, James Thomas, Ginny Brunton. Anne-Marie Bagnall and Kris Southby, Leeds Beckett University, undertook a scoping review for this publication. © Crown copyright 2015 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email [email protected]. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. Any enquiries regarding this publication should be sent to [email protected]. Published February 2015 PHE publications gateway number: 2014711 2 Community-centred approaches for health and wellbeing Contents About Public Health England 2 Foreword 4 Executive summary 5 Introduction 7 Why work with communities? 8 Communities as building blocks for health 11 A family of community-centred approaches 15 Health outcomes and evidence 31 Conclusion 36 Appendix 1.
    [Show full text]
  • UK Field Epidemiology Training Programme Prospectus 2021 the UK Field Epidemiology Training Programme
    UK Field Epidemiology Training Programme Prospectus 2021 The UK Field Epidemiology Training Programme The Field Epidemiology Training Programme (FETP) is a full-time two-year fellowship programme, which provides training and practical experience in intervention epidemiology and aims to develop specialist field On-the-job epidemiology skills. Training is provided mainly through on-the-job service provision and learning activities, but at least ten percent of time will be dedicated to formally taught training courses. The programme currently covers England, Wales and Northern Ireland. Conferences Courses There are 12 training sites. The majority are within Field Service (FS) teams. These teams are part of a nationally coordinated and managed service that is geographically dispersed with specialist field epidemiology teams spread across England. In addition, there are sites in National Centres (NC) and Health Protections Teams (HPT), who provide specialist public health advice and operational support to NHS/local authorities etc., and in the Centre for Radiation, Chemicals and Environmental Hazards (CRCE). Belfast Newcastle NC FS Liverpool Leeds FS FS Birmingham Nottingham FS FS Cardiff Cambridge NC FS/HPT Bristol London FS FS Oxford London CRCE/HPT NC 2 UK FETP goals 1. To strengthen capacity and provision of public health epidemiology 2. To develop a network of skilled field epidemiologists with a shared sense of purpose, working to common standards across the UK and Europe 3. To raise the profile of field epidemiology and embed this into everyday health protection practice 4. To support PHE’s global public health workplan through provision of fellows and staff to support international response and capacity building Graduation Criteria These are the minimum criteria to pass the programme but the fellowship has flexibility and time to support multiple projects in different areas, based on the needs of individual fellows.
    [Show full text]
  • Health Inequalities Resources
    Health Inequalities Resources This is a resource to support teams in meeting their health inequalities duties by signposting you to key publically available resources. This is not intended to be a definitive list. However, we are keen to update this regularly. Please do therefore let us know if you have a suggestion for any additional resources to be added? Please email these to [email protected] NHS England/ Public Health England (PHE)/ other – general resources Heath Inequalities Intervention Toolkit (Spearhead): http://www.lho.org.uk/LHO_Topics/Analytic_Tools/HealthInequalitiesInterventionToolkit.aspx PHE Longer Lives website: http://healthierlives.phe.org.uk/ Centre for Local Economic Strategies/ PHE - Due North: The report of the Inquiry on Health Equity for the North: http://www.cles.org.uk/news/inquiry-publishes-due-north-report-on-health-equity/ PHE National conversation on Health Inequalities: Report of event held on 25th June 2014: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/356982/National_ Conversations_Report_19_Sept.pdf NHS England Dec 2013 Board paper – Promoting Equality and Tackling Health Inequalities: http://www.england.nhs.uk/wp-content/uploads/2013/12/brd-dec-1.pdf PHE Health Equity Assessment Tool: PHE Priorities - From evidence into action: opportunities to protect and improve the nation’s health: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/366852/PHE_Prior ities.pdf NHS England – Guidance for NHS Commissioners on Equality and Health Inequalities Legal
    [Show full text]
  • How Your Information Is Shared So That This Practice Can Meet Legal
    How your information is shared so that this practice can meet legal requirements The law requires Devonport Health Centre to share information from your medical records in certain circumstances. Information is shared so that the NHS or Public Health England can, for example: plan and manage services; check that the care being provided is safe; prevent infectious diseases from spreading. We will share information with NHS Digital, the Care Quality Commission and local health protection team (or Public Health England) when the law requires us to do so. Please see below for more information. We must also share your information if a court of law orders us to do so. NHS Digital NHS Digital is a national body which has legal responsibilities to collect information about health and social care services. It collects information from across the NHS in England and provides reports on how the NHS is performing. These reports help to plan and improve services to patients. This practice must comply with the law and will send data to NHS Digital, for example, when it is told to do so by the Secretary of State for Health or NHS England under the Health and Social Care Act 2012. More information about NHS Digital and how it uses information can be found at: https://digital.nhs.uk/home NHS Digital sometimes shares names and addresses of patients suspected of committing immigration offences with the Home Office. More information on this can be found here: https://www.gov.uk/government/publications/information-requests- from-the-home-office-to-nhs-digital Care Quality Commission (CQC) The CQC regulates health and social care services to ensure that safe care is provided.
    [Show full text]
  • SARS-Cov-2 Variants of Concern and Variants Under Investigation in England
    SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 20 6 August 2021 This briefing provides an update on previous briefings up to 23 July 2021 1 SARS-CoV-2 variants of concern and variants under investigation Contents Summary ............................................................................................................................. 3 Published information on variants ................................................................................... 4 Part 1: Surveillance overview .............................................................................................. 5 1.1 Variants under surveillance ....................................................................................... 5 1.2 Sequencing coverage ................................................................................................ 7 1.3 VOC and VUI case numbers, proportion, deaths and case fatality rate ................... 11 1.4 Variant prevalence ................................................................................................... 21 1.5 Antigenic change over time (international) .............................................................. 26 1.6 Secondary attack rates ............................................................................................ 30 1.7 Vaccination .............................................................................................................. 35 1.8 Updates from Variant Technical Group members...................................................
    [Show full text]
  • Sector-Led Improvement Conference Brochure
    Association of the Directors of Public Health Yorkshire and the Humber Sector-led improvement conference brochure Making the link: evidence and practice Friday 17 February 2017, Royal York Hotel, York Programme 9.30 Arrival and registration 10.00 Introduction and housekeeping (Tim Allison, DPH, East Riding of Yorkshire Council) 10.05 Welcome to York from City of York council (Councillor Carol Runciman, Chair of the York Health and Wellbeing Board) 10.15 Keynote presentation: We can solve poverty in the UK (title TBC). Chris Goulden, Deputy Director of Policy and Research, Joseph Rowntree Foundation 11.00 Whole system community-centred approaches for health and wellbeing: evidence into action. Jane South, Professor of Healthy Communities, Leeds Beckett University and Public Health England 11.20 Break 11.45 Parallel sessions: oral abstract presentations 13.00 Lunch and poster presentations 14.00 Parallel sessions: Communities of Improvement, practitioner registration scheme and linking practice and evidence 15.30 Final plenary (Andrew Furber, DPH Wakefield and President, ADsPH) 15.50 Closing remarks (Tim Allison, DPH, East Riding of Yorkshire Council) 16.00 Close Please Tweet using #YHSLI2017 Parallel sessions The morning sessions will feature the oral abstract presentations with the opportunity to attend three sessions. After lunch you will be able to attend two sessions relating to the work of the Communities of Improvement, a workshop focusing on the links between practice and evidence or a workshop on the forthcoming public health practitioner registration programme. The schedule for the sessions can be found at the end of this conference brochure. Poster presentations can be viewed during the coffee and lunch breaks.
    [Show full text]